Last reviewed · How we verify
Ciclesonide Inhalation Aerosol
At a glance
| Generic name | Ciclesonide Inhalation Aerosol |
|---|---|
| Also known as | Alvesco |
| Sponsor | Ola Blennow, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422) (PHASE4)
- Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (PHASE2)
- Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis (PHASE4)
- Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis (PHASE3)
- A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciclesonide Inhalation Aerosol CI brief — competitive landscape report
- Ciclesonide Inhalation Aerosol updates RSS · CI watch RSS
- Ola Blennow, MD, PhD portfolio CI